Otsuka Pharmaceutical Co., Ltd. /
iBio, Inc.
Otsuka Pharmaceutical Co., Ltd. buys iBio PD-1 assets
What happened
Otsuka Pharmaceutical Co., Ltd. purchased iBio, Inc.’s PD-1 agonist assets, with the acquisition closing on Feb. 25, 2024.
The agreement provides for $1,000,000 paid at closing, plus potential payments tied to development and commercialization milestones.
The source
Everything on this page comes from the source below.
Otsuka Pharmaceutical Co., Ltd. buys iBio PD-1 assets
This document is the source for the companies, stage and people on this page.
Original filingUnlock with ProTimeline
Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.
Closed
The source this page is built from.
Source-verifiedPublished by the source
The source this page is built from.
Source-verified
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Request an inviteAlready invited? Sign in
Carrywatch Pro is by invitation. An invite lets you buy Pro.
By email · Weekly